Cells, stem cells, and cancer stem cells

Seminars in Reproductive Medicine

Volumn 31, Issue 1, 2013, Pages 5-13

  Aguilar Gallardo, Cristóbal ^a   Simón, Carlos ^a,b  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^b Instituto Universitario IVI INCLIVA   (Spain)

Author keywords

cancer stem cell; microenvironment; stem cells

Indexed keywords

ARTICLE; BLASTOMA; BLOOD; BLOOD CELL; BONE; BRAIN; CANCER RESISTANCE; CANCER STEM CELL; CARTILAGE; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL RENEWAL; CELL THERAPY; CELLS; ECTODERM; EGG; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; ENDODERM; GAMETOGENESIS; GENE OVEREXPRESSION; HEART MUSCLE CELL; HUMAN; IN VITRO STUDY; INTESTINE; LIVER; LUNG; MESODERM; MULTIPOTENT STEM CELL; MUSCLE; NERVE CELL; NONHUMAN; NUCLEAR REPROGRAMMING; OVARY CANCER; PANCREAS CELL; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REPRODUCTION; SKIN; SOMATIC CELL; SPERM; STEM CELL;

ANIMALS; CELL DIFFERENTIATION; EMBRYONIC DEVELOPMENT; EMBRYONIC STEM CELLS; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; PLURIPOTENT STEM CELLS;

EID: 84872375754     PISSN: 15268004     EISSN: 15264564     Source Type: Journal    
DOI: 10.1055/s-0032-1331792     Document Type: Article

References (66)

1. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell: 2006; 126 4 663 676 (Pubitemid 44233629)
2. Thomson J. A., Itskovitz-Eldor J., Shapiro S. S., et al. Embryonic stem cell lines derived from human blastocysts. Science: 1998; 282 5391 1145 1147 (Pubitemid 28516247)
3. Turetsky T., Aizenman E., Gil Y., et al. Laser-assisted derivation of human embryonic stem cell lines from IVF embryos after preimplantation genetic diagnosis. Hum Reprod: 2008; 23 1 46 53 (Pubitemid 351767322)
4. Valbuena D., Galán A., Sánchez E., et al. Derivation and characterization of three new Spanish human embryonic stem cell lines (VAL -3 -4 -5) on human feeder and in serum-free conditions. Reprod Biomed Online: 2006; 13 6 875 886 (Pubitemid 46019340)
5. Klimanskaya I., Chung Y., Meisner L., Johnson J., West M. D., Lanza R. Human embryonic stem cells derived without feeder cells. Lancet: 2005; 365 9471 1636 1641 (Pubitemid 40693413)
6. Klimanskaya I., Chung Y., Becker S., Lu S. J., Lanza R. Human embryonic stem cell lines derived from single blastomeres. Nature: 2006; 444 7118 481 485 (Pubitemid 44809064)
7. Chung Y., Klimanskaya I., Becker S., et al. Embryonic and extraembryonic stem cell lines derived from single mouse blastomeres. Nature: 2006; 439 7073 216 219 (Pubitemid 43083144)
8. Forbes S., Vig P., Poulsom R., Thomas H., Alison M. Hepatic stem cells. J Pathol: 2002; 197 4 510 518
9. Pittenger M. F., Mackay A. M., Beck S. C., et al. Multilineage potential of adult human mesenchymal stem cells. Science: 1999; 284 5411 143 147 (Pubitemid 29282067)
10. Zuk P. A., Zhu M., Mizuno H., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng: 2001; 7 2 211 228 (Pubitemid 32295155)
11. Bieback K., Kern S., Klüter H., Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells: 2004; 22 4 625 634 (Pubitemid 39014578)
12. Jiang Y., Vaessen B., Lenvik T., Blackstad M., Reyes M., Verfaillie C. M. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol: 2002; 30 8 896 904 (Pubitemid 34845893)
13. Zhou S., Schuetz J. D., Bunting K. D., et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med: 2001; 7 9 1028 1034 (Pubitemid 32937383)
14. Brazelton T. R., Rossi F. M., Keshet G. I., Blau H. M. From marrow to brain: expression of neuronal phenotypes in adult mice. Science: 2000; 290 5497 1775 1779 (Pubitemid 32004810)
15. Yoon J., Choi S. C., Park C. Y., et al. Bone marrow-derived side population cells are capable of functional cardiomyogenic differentiation. Mol Cells: 2008; 25 2 216 223 (Pubitemid 351818998)
16. Sadek H. A., Martin C. M., Latif S. S., Garry M. G., Garry D. J. Bone-marrow-derived side population cells for myocardial regeneration. J Cardiovasc Transl Res: 2009; 2 2 173 181
17. Krause D. S., Theise N. D., Collector M. I., et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell: 2001; 105 3 369 377 (Pubitemid 32455343)
18. Horwitz E. M., Prockop D. J., Fitzpatrick L. A., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med: 1999; 5 3 309 313 (Pubitemid 29124367)
19. Wang L., Menendez P., Cerdan C., Bhatia M. Hematopoietic development from human embryonic stem cell lines. Exp Hematol: 2005; 33 9 987 996 (Pubitemid 41225422)
20. Trounson A. The production and directed differentiation of human embryonic stem cells. Endocr Rev: 2006; 27 2 208 219
21. Takahashi K., Tanabe K., Ohnuki M., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell: 2007; 131 5 861 872 (Pubitemid 350138099)
22. Yu J., Vodyanik M. A., Smuga-Otto K., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science: 2007; 318 5858 1917 1920
23. Szabo E., Rampalli S., Risueño R. M., et al. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature: 2010; 468 7323 521 526
24. Kim J. B., Greber B., Araúzo-Bravo M. J., et al. Direct reprogramming of human neural stem cells by OCT4. Nature: 2009; 461 7264 649 3
25. Marión R. M., Strati K., Li H., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature: 2009; 460 7259 1149 1153
26. Hong H., Takahashi K., Ichisaka T., et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature: 2009; 460 7259 1132 1135
27. Kawamura T., Suzuki J., Wang Y. V., et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature: 2009; 460 7259 1140 1144
28. Soldner F., Hockemeyer D., Beard C., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell: 2009; 136 5 964 977
29. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science: 2008; 322 5903 949 953
30. Kaji K., Norrby K., Paca A., Mileikovsky M., Mohseni P., Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature: 2009; 458 7239 771 775
31. Yu J., Hu K., Smuga-Otto K., et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science: 2009; 324 5928 797 801
32. Marro S., Pang Z. P., Yang N., et al. Direct lineage conversion of terminally differentiated hepatocytes to functional neurons. Cell Stem Cell: 2011; 9 4 374 382
33. Carvajal-Vergara X., Sevilla A., D'Souza S. L., et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature: 2010; 465 7299 808 812
34. Raya A., Rodríguez-Pizà I., Guenechea G., et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature: 2009; 460 7251 53 59
35. Urbach A., Bar-Nur O., Daley G. Q., Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell: 2010; 6 5 407 411
36. Wunderlich V. JMM-past and present. Chromosomes and cancer: Theodor Boveri's predictions 100 years later. J Mol Med (Berl): 2002; 80 9 545 548
37. Clarke M. F., Dick J. E., Dirks P. B., et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res: 2006; 66 19 9339 9344 (Pubitemid 44623625)
38. Ruiz-Vela A., Aguilar-Gallardo C., Simón C. Building a framework for embryonic microenvironments and cancer stem cells. Stem Cell Rev: 2009; 5 4 319 327
39. Bonnet D., Dick J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med: 1997; 3 7 730 737 (Pubitemid 27298715)
40. Al-Hajj M., Wicha M. S., Benito-Hernandez A., Morrison S. J., Clarke M. F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A: 2003; 100 7 3983 3988 (Pubitemid 36418143)
41. Bapat S. A., Mali A. M., Koppikar C. B., Kurrey N. K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res: 2005; 65 8 3025 3029 (Pubitemid 40524578)
42. Zhang S., Balch C., Chan M. W., et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res: 2008; 68 11 4311 4320
43. Ginestier C., Hur M. H., Charafe-Jauffret E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell: 2007; 1 5 555 567 (Pubitemid 350056407)
44. Haraguchi N., Utsunomiya T., Inoue H., et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells: 2006; 24 3 506 513 (Pubitemid 44464754)
45. Ishii H., Iwatsuki M., Ieta K., et al. Cancer stem cells and chemoradiation resistance. Cancer Sci: 2008; 99 10 1871 1877
46. Clarke A. R. Wnt signalling in the mouse intestine. Oncogene: 2006; 25 57 7512 7521 (Pubitemid 44885750)
47. Wang S., Yang D., Lippman M. E. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol: 2003; 30 5 16 133 142 (Pubitemid 37433404)
48. Wicha M. S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res: 2006; 66 4 1883 1890; discussion 1895-1896
49. Hosonuma S., Kobayashi Y., Kojo S., et al. Clinical significance of side population in ovarian cancer cells. Hum Cell: 2011; 24 1 9 12
50. Lu L., Katsaros D., Wiley A., Rigault de la Longrais I. A., Puopolo M., Yu H. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncol Res: 2007; 16 8 395 403 (Pubitemid 47413256)
51. Ferlay J., Parkin D. M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer: 2010; 46 4 765 781
52. Piek J. M., van Diest P. J., Verheijen R. H. Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Biol: 2008; 622 79 87
53. Kurrey N. K., Jalgaonkar S. P., Joglekar A. V., et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells: 2009; 27 9 2059 2068
54. Fraser M., Leung B. M., Yan X., Dan H. C., Cheng J. Q., Tsang B. K. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res: 2003; 63 21 7081 7088 (Pubitemid 37413443)
55. Fraser M., Bai T., Tsang B. K. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer: 2008; 122 3 534 546 (Pubitemid 350308944)
56. Levine A. J., Puzio-Kuter A. M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science: 2010; 330 6009 1340 1344
57. Gustafsson M. V., Zheng X., Pereira T., et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell: 2005; 9 5 617 628 (Pubitemid 41555144)
58. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature: 2011; 474 7353 609 615
59. Shayesteh L., Lu Y., Kuo W. L., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet: 1999; 21 1 99 102 (Pubitemid 29036292)
60. Obata K., Morland S. J., Watson R. H., et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res: 1998; 58 10 2095 2097 (Pubitemid 28232892)
61. Esteller M., Silva J. M., Dominguez G., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst: 2000; 92 7 564 569 (Pubitemid 30212318)
62. Kwong J., Lee J. Y., Wong K. K., et al. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia: 2006; 8 4 268 278
63. Barton C. A., Clark S. J., Hacker N. F., O'Brien P. M. Epigenetic markers of ovarian cancer. Adv Exp Med Biol: 2008; 622 35 51
64. Woloszynska-Read A., James S. R., Link P. A., Yu J., Odunsi K., Karpf A. R. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun: 2007; 7 21
65. Bram E. E., Stark M., Raz S., Assaraf Y. G. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia: 2009; 11 12 1359 1370
66. Boylan K. L., Misemer B., Derycke M. S., et al. Claudin 4 is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation. Int J Mol Sci: 2011; 12 2 1334 1358